KYN-5356 / Kynexis - LARVOL DELTA

Cognision Announces Partnership with Kynexis to Utilize its COGNISION System in a Phase 2 Trial of KYN-5356 in Subjects with Schizophrenia (PRNewswire) - "The ongoing Phase 2 study is designed to establish proof of clinical concept for KYN-5356 by demonstrating its efficacy in improving cognitive performance. Kynexis chose to partner with Cognision and utilize the COGNISION System to precisely measure drug-induced changes in brain function. The measurements that are obtained during EEG and ERP testing sessions, conducted after the administration of either KYN-5356 or a placebo, have the ability to link therapeutic effects with objective biomarkers related to the mechanism of action and disease biology."

Biomarker • Licensing / partnership • Schizophrenia

A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia (clinicaltrials.gov) - P2 | N=150 | Recruiting | Sponsor: Kynexis B.V.

New P2 trial • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Psychiatry • Schizophrenia

KYN5356-CL-001: A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of KYN-5356 in Healthy Subjects Aged 18 to 55 Years (clinicaltrials.gov) - P1 | N=72 | Completed | Sponsor: Kynexis B.V. | Active, not recruiting ➔ Completed

Trial completion • CNS Disorders • Cognitive Disorders • Psychiatry • Schizophrenia

KYN5356-CL-001: A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of KYN-5356 in Healthy Subjects Aged 18 to 55 Years (clinicaltrials.gov) - P1 | N=80 | Active, not recruiting | Sponsor: Kynexis B.V. | Recruiting ➔ Active, not recruiting | Trial completion date: Jul 2024 ➔ Nov 2024 | Trial primary completion date: Jul 2024 ➔ Nov 2024

Enrollment closed • Trial completion date • Trial primary completion date • CNS Disorders • Cognitive Disorders • Psychiatry • Schizophrenia

Anthranilic Acid, a GPR109A Agonist, and Schizophrenia. (PubMed, Int J Tryptophan Res) - "Future research might explore antipsychotic effects of (1) human pegylated kynureninase, an enzyme that catalyzes formation of AA from kynurenine (Kyn); (2) inhibitors of Kyn conversion into kynurenic acid, for example, KYN5356, to patients with already impaired Kyn conversion into 3-hydroxykynurenine; (3) synthetic GPR 109A agonists, for example, MK-1903 and SCH900271 and GSK256073, that underwent clinical trials as anti-dyslipidemia agents. GPR109A expression, that might be a new endophenotype of schizophrenia, especially associated with cognitive impairment, needs thorough assessment."

Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dyslipidemia • Metabolic Disorders • Psychiatry • Schizophrenia • KYNU